Catalog No.
DHC33301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
Fab-G1-kappa
Clonality
Monoclonal
Target
CD41, ITGAB, GPIIb, ITGA2B, Platelet membrane glycoprotein IIb, GP2B, Integrin alpha-IIb, GPalpha IIb, GPIIIa, Integrin beta-3, CD61, ITGB3, Platelet membrane glycoprotein IIIa, GP3A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08514 & P05106
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
c7E3, CAS: 143653-53-6
Clone ID
Abciximab
[Abciximab], PMID: 17465067
How abciximab might be clinically useful, PMID: 27519521
Cryo-Electron Microscopy Structure of the αIIbβ3-Abciximab Complex, PMID: 31969014
Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions, PMID: 21204736
ABCIXIMAB: a new antiaggregant used in angioplasty, PMID: 8833561
Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation, PMID: 10724797
Abciximab/Heparin During Acute Heparin-Induced Thrombocytopenia: A Word of Caution, PMID: 29305853
Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease, PMID: 7528131
A review of intracoronary abciximab in percutaneous coronary interventions--where are we now and where do we go from here?, PMID: 23957238
Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions, PMID: 21942506
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention, PMID: 20234778
Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting, PMID: 30845955
Current status of cardiac surgery in the abciximab-treated patient, PMID: 10966006
Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction, PMID: 30418157
Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact, PMID: 33041442
Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction, PMID: 14727961
Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention, PMID: 30460974
Intracoronary Abciximab in Diabetic STEMI Patients: Questionable Benefit, Proven Harm, PMID: 27515334
Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach?, PMID: 16891291
Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients, PMID: 27366874
Clinical experience in coronary bypass surgery for abciximab-treated patients, PMID: 10966008
Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications, PMID: 11033455
Reply, PMID: 29371038
On the use of abciximab in percutaneous coronary intervention, PMID: 21827726
Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment, PMID: 30154253
Cangrelor or Abciximab as First Choice in Cardiogenic Shock, PMID: 29217012
Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis, PMID: 31542257
In situ administration of abciximab for thrombus resolution during intracranial bypass surgery: case report, PMID: 29350605
Understanding the complexity of abciximab-related thrombocytopenia, PMID: 20135055
Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial, PMID: 22447888
Use of intravenous abciximab as adjunctive therapy for carotid angioplasty and stent placement, PMID: 12745860
Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock, PMID: 29217013
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials, PMID: 15827315
Bilateral subconjunctival hemorrhage secondary to abciximab use: case report, PMID: 29267537
Abciximab and excessive bleeding in patients undergoing emergency cardiac operations, PMID: 9485247
Thromboaspiration and IIb/IIIa therapy in STEMI: abciximab redux?, PMID: 24078419
[Abciximab in the treatment of acute coronary syndromes by angioplasty and stents], PMID: 9806003
Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?, PMID: 11773572
Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis, PMID: 12112910
Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis, PMID: 20516508
Abciximab extends treatment window for stroke, PMID: 12849109
Intracoronary abciximab in STEMI using local drug delivery catheter - single center experience, PMID: 23809377
Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up, PMID: 17251257
Periprocedural abciximab administration in ST elevation myocardial infarction patients. Effect on severe microvascular obstruction beyond the restoration of epicardial coronary flow by primary angioplasty, PMID: 17971662
Readministration of abciximab in percutaneous coronary intervention, PMID: 10745525
Concentration-dependent effect of abciximab on platelets and neutrophils in a model of cardiopulmonary bypass, PMID: 17312858
High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study, PMID: 24831494
Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction, PMID: 12587942
Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor, PMID: 16015412
Stenting and abciximab in primary angioplasty: a review of current status, PMID: 16320920
For research use only. Not for human or drug use.
